Alector Stock Quote ALEC - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

5.15

Bid

5.14

Ask

5.16

Volume

157,900

5.10 Day's Range 5.49

3.66 52 Week Range 8.90

Market Cap

501.203M

Previous Close

5.45

Open

5.49

Last Trade

5.1482

Last Trade Time

14:16:29

Financial Volume

$ 823,474

VWAP

5.2152

Average Volume (3m)

537,019

Shares Outstanding

97,321,062

Dividend Yield

PE Ratio

-3.84

Earnings Per Share (EPS)

-1.34

Revenue

97.06M

Net Profit

-130.39M

Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.alector.com

Headquarters

Wilmington, Delaware, USA

Founded

Alector Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALEC. The last closing price for Alector was $5.45. Over the last year, Alector shares have traded in a share price range of $ 3.66 to $ 8.90.

Alector currently has 97,321,062 shares outstanding. The market capitalization of Alector is $530.40 million. Alector has a price to earnings ratio (PE ratio) of -3.84.

FeaturedCannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

FeaturedIntegrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.56	-9.80735551664	5.71	6.37	5.1	933041	5.73320736	CS
4	-0.19	-3.55805243446	5.34	6.37	4.47	580527	5.49053241	CS
12	0.75	17.0454545455	4.4	6.78	4.22	537019	5.56072336	CS
26	-0.81	-13.5906040268	5.96	6.78	4.11	580786	5.3263574	CS
52	-1.08	-17.3354735152	6.23	8.9	3.66	635642	5.83744747	CS
156	-18.88	-78.5684560965	24.03	27	3.66	610515	9.44792192	CS
260	-13.86	-72.9089952656	19.01	45	3.66	666518	15.34930076	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MSSMaison Solutions Inc	$ 1.50 (109.79%)	88.35M
BNZIBanzai International Inc	$ 7.449 (77.36%)	54.25M
SEELSeelos Therapeutics Inc	$ 0.334 (75.79%)	316.1M
NUZENuZee Inc	$ 0.90 (60.60%)	3.53M
XHGXChange TED Inc	$ 0.9499 (53.33%)	24.33M
BIVIBioVie Inc	$ 1.1472 (-59.03%)	2.31M
GHSIGuardion Health Sciences Inc	$ 7.09 (-32.60%)	338.83k
XPONExpion360 Inc	$ 0.0891 (-23.85%)	37.78M
VEROVenus Concept Inc	$ 0.6151 (-23.29%)	365.29k
LEDSSemiLEDS Corporation	$ 0.99 (-21.43%)	177.48k
SEELSeelos Therapeutics Inc	$ 0.334 (75.79%)	316.1M
NVDANVIDIA Corporation	$ 121.25 (4.29%)	249.23M
SQQQProShares UltraPro Short QQQ	$ 7.675 (-1.22%)	111.79M
MSSMaison Solutions Inc	$ 1.50 (109.79%)	88.35M
MLGOMicroAlgo Inc	$ 0.2085 (5.09%)	86.86M